FDA Approves New Drug to Delay Type 1 Diabetes Progression in Youth

The U.S. Food and Drug Administration has granted approval for Sanofi's drug, Tzield (teplizumab), for use in children aged 8 to 17. This medication is designed to slow the advancement of type 1 diabetes, offering a new treatment option for pediatric patients. This development represents a significant step forward in managing the disease in younger populations.